← Leaderboards
Marcus Aaron Horwitz
University Of California San Francisco
$40,522,782
Attributed
$43,142,921
Total exposure
21
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,142,921 · 21
By mechanism
R01$36,507,073 · 12
U54$3,504,188 · 2
R56$2,004,530 · 3
R21$1,117,250 · 3
P41$9,880 · 1
Top collaborators
- Z Hong Zhou6 shared
- Deepak Kaushal2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Kamal K Sen$2,384,141
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsBioterrorismProteinsMycobacterium TuberculosisBacteriaMacrophageVirulentPathogenFrancisella TularensisTuberculosisVirulenceDoseVaccinesAerosolsGrowthInfectionRecombinantsSafetyAntibioticsLifeAttenuatedAntigensImmunityTuberculosis Vaccines
Grant awards (80)
Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection$931,829
R01 · FY2025 · AI · contact PI
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance$756,592
R01 · FY2025 · AI · contact PI
Identification by High Throughput Screening of Inhibitors of the Mycobacterium tuberculosis ESX-1 and ESX-5 Type VII Secretion Systems â critical virulence determinants and novel drug targets$236,250
R21 · FY2025 · AI · contact PI
Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection$934,898
R01 · FY2024 · AI · contact PI
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance$779,991
R01 · FY2024 · AI · contact PI
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence$549,664
R01 · FY2024 · AI · contact PI
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance$779,991
R01 · FY2023 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$620,702
R01 · FY2023 · AI · contact PI
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence$549,664
R01 · FY2023 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$155,111
R01 · FY2023 · AI · contact PI
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis$1,200,711
R01 · FY2022 · AI · contact PI
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance$779,991
R01 · FY2022 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$620,702
R01 · FY2022 · AI · contact PI
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence$549,664
R01 · FY2022 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$155,110
R01 · FY2022 · AI · contact PI
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis$1,205,608
R01 · FY2021 · AI · contact PI
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance$779,991
R01 · FY2021 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$775,812
R01 · FY2021 · AI · contact PI
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence$549,664
R01 · FY2021 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$155,110
R01 · FY2021 · AI · contact PI
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis$1,158,564
R01 · FY2020 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$620,702
R01 · FY2020 · AI · contact PI
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence$549,664
R01 · FY2020 · AI · contact PI
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis$939,379
R01 · FY2019 · AI · contact PI
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform$789,812
R01 · FY2019 · AI · contact PI
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis$968,076
R01 · FY2018 · AI · contact PI
Composition, structure, and mutational analysis of the Francisella Type VI Secretion System$625,231
R56 · FY2018 · AI · contact PI
Identification by High Throughput Screening of Inhibitors of Assembly and Secretion of the Francisella Type VI Secretion System$192,500
R21 · FY2017 · AI · contact PI
Pre-Exposure Prophylaxis Against Francisella tularensis$706,654
R01 · FY2016 · AI · contact PI
Identification by High Throughput Screening of Inhibitors of Assembly and Secretion of the Francisella Type VI Secretion System$231,000
R21 · FY2016 · AI · contact PI
Pre-Exposure Prophylaxis Against Francisella tularensis$706,654
R01 · FY2015 · AI · contact PI
Pre-Exposure Prophylaxis Against Francisella tularensis$706,654
R01 · FY2014 · AI · contact PI
Pre-Exposure Prophylaxis Against Francisella tularensis$546,688
R01 · FY2013 · AI · contact PI
Intracellular Biology of Francisella tularensis$339,039
U54 · FY2013 · AI · contact PI
Pre-Exposure Prophylaxis Against Francisella tularensis$709,102
R56 · FY2012 · AI · contact PI
Intracellular Biology of Francisella tularensis$336,081
U54 · FY2012 · AI · contact PI
Intracellular Biology of Francisella tularensis$373,053
U54 · FY2011 · AI · contact PI
Development and Testing of New Tuberculosis Vaccines$721,686
R01 · FY2010 · AI · contact PI
A TB Vaccine for AIDS Patients$683,780
R01 · FY2010 · AI · contact PI
Development of a tularemia vaccine that is safer and more potent than LVS$670,197
R56 · FY2010 · AI · contact PI
Intracellular Biology of Francisella tularensis$360,519
U54 · FY2010 · AI · contact PI
Development and Testing of New Tuberculosis Vaccines$709,646
R01 · FY2009 · AI · contact PI
A TB Vaccine for AIDS Patients$672,892
R01 · FY2009 · AI · contact PI
Intracellular Biology of Francisella tularensis$360,986
U54 · FY2009 · AI · contact PI
Development and Testing of New Tuberculosis Vaccines$690,878
R01 · FY2008 · AI · contact PI
A TB Vaccine for AIDS Patients$655,618
R01 · FY2008 · AI · contact PI
Intracellular Biology of Francisella Tularensis$470,339
U54 · FY2008 · AI · contact PI
Novel Antimicrobial Agents Against M. tuberculosis$454,104
R01 · FY2008 · AI · contact PI
Development and Testing of New Tuberculosis Vaccines$685,682
R01 · FY2007 · AI · contact PI
A TB Vaccine for AIDS Patients$651,218
R01 · FY2007 · AI · contact PI
Characterization of the M. tuberculosis phagosome$522,110
R01 · FY2007 · HL · contact PI
Intracellular Biology of Francisella Tularensis$458,189
U54 · FY2007 · AI · contact PI
Novel Antimicrobial Agents Against M. tuberculosis$450,927
R01 · FY2007 · AI · contact PI
Development and Testing of New Tuberculosis Vaccines$686,321
R01 · FY2006 · AI · contact PI
A TB Vaccine for AIDS Patients$653,571
R01 · FY2006 · AI · contact PI
Characterization of the M. tuberculosis phagosome$509,121
R01 · FY2006 · HL · contact PI
Novel Antimicrobial Agents Against M. tuberculosis$451,198
R01 · FY2006 · AI · contact PI
Intracellular Biology of Francisella Tularensis$416,642
U54 · FY2006 · AI · contact PI
Characterization of the M. tuberculosis phagosome$508,460
R01 · FY2005 · HL
Novel Antimicrobial Agents Against M. tuberculosis$448,875
R01 · FY2005 · AI
Intracellular Biology of Francisella Tularensis$389,340
U54 · FY2005 · AI
DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES$616,092
R01 · FY2004 · AI
Characterization of the M. tuberculosis phagosome$493,806
R01 · FY2004 · HL
Novel Antimicrobial Agents Against M. tuberculosis$158,286
R01 · FY2004 · AI
DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES$598,148
R01 · FY2003 · AI
Characterization of the M. tuberculosis phagosome$490,463
R01 · FY2003 · HL
Characterization of the Francisella tularensis phagosome$228,750
R21 · FY2003 · AI
DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES$515,014
R01 · FY2002 · AI
M TUBERCULOSIS PHAGOSOME$352,658
R01 · FY2002 · AI
M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT &INHIBITION$278,313
R01 · FY2002 · AI
Characterization of the Francisella tularensis phagosome$228,750
R21 · FY2002 · AI
ROLE OF EXOCHELINS IN TUBERCULOSIS &AIDS$0
P41 · FY2002 · RR
DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES$565,351
R01 · FY2001 · AI
M TUBERCULOSIS PHAGOSOME$343,745
R01 · FY2001 · AI
M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT &INHIBITION$270,206
R01 · FY2001 · AI
ROLE OF EXOCHELINS IN TUBERCULOSIS &AIDS$0
P41 · FY2001 · RR
DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES$549,184
R01 · FY2000 · AI
M TUBERCULOSIS PHAGOSOME$333,731
R01 · FY2000 · AI
M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT &INHIBITION$262,337
R01 · FY2000 · AI
ROLE OF EXOCHELINS IN TUBERCULOSIS &AIDS$9,880
P41 · FY2000 · RR